Latest Articles
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk
Published: July 15, 2026, 11:49 p.m.
Leven Rambin reveals life-threatening surgery complication after endometriosis procedure - MSN
Leven Rambin reveals life-threatening surgery complication after endometriosis procedure MSN
Published: July 15, 2026, 9:13 p.m.
The many potential symptoms of endometriosis - Contemporary OB/GYN
The many potential symptoms of endometriosis Contemporary OB/GYN
Published: July 15, 2026, 8 p.m.
Dual Chamber Prefilled Syringes Market Size, Industry Analysis, Demand & Forecast 2035 - Global Growth Insights
Dual Chamber Prefilled Syringes Market Size, Industry Analysis, Demand & Forecast 2035 Global Growth Insights
Published: July 15, 2026, 7:28 p.m.
Clinical and surgical diagnosis of endometriosis, with Heather Appelbaum, MD - Contemporary OB/GYN
Clinical and surgical diagnosis of endometriosis, with Heather Appelbaum, MD Contemporary OB/GYN
Published: July 15, 2026, 5:16 p.m.
US Says Ceasefire Is Holding Despite Iran's Attacks In The Strait Of Hormuz And Against The UAE Endometriosis (t3A5vggIfI) - Mshale
US Says Ceasefire Is Holding Despite Iran's Attacks In The Strait Of Hormuz And Against The UAE Endometriosis (t3A5vggIfI) Mshale
Published: July 15, 2026, 4:26 p.m.
Two tests GPs can soon offer to help spot endometriosis - AOL.com
Two tests GPs can soon offer to help spot endometriosis AOL.com
Published: July 15, 2026, 4:06 p.m.
Rethinking Endometriosis: A Whole-Body Disease - Yale Medicine
Rethinking Endometriosis: A Whole-Body Disease Yale Medicine
Published: July 15, 2026, 4:01 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace
Published: July 15, 2026, 3:11 p.m.
New Flo and Mayo Clinic Research Finds Widespread Confusion About Perimenopause Onset - Femtech Insider
New Flo and Mayo Clinic Research Finds Widespread Confusion About Perimenopause Onset Femtech Insider
Published: July 15, 2026, 12:41 p.m.
Link copied to clipboard!